Title : Hep B reactivation common during direct-acting antiviral therapy for hep C
link : Hep B reactivation common during direct-acting antiviral therapy for hep C
Hep B reactivation common during direct-acting antiviral therapy for hep C
Reuters Health
Last Updated: 2018-02-02
By Will Boggs MD
NEW YORK (Reuters Health) - Hepatitis B virus (HBV) reactivation is common in patients with chronic HBV and hepatitis C virus (HCV) coinfection receiving direct-acting antiviral (DAA) therapy, according to a systematic review and meta-analysis.
"It is important to identify patients at risk of HBV reactivation," said Dr. Johannes Vermehren from University Hospital Frankfurt, in Frankfurt am Main, Germany.
By Will Boggs MD
NEW YORK (Reuters Health) - Hepatitis B virus (HBV) reactivation is common in patients with chronic HBV and hepatitis C virus (HCV) coinfection receiving direct-acting antiviral (DAA) therapy, according to a systematic review and meta-analysis.
"HBsAg-positive patients who also have detectable HBV DNA should be closely monitored when treated for hepatitis C with direct antivirals. Alternatively, (nucleoside/nucleotide) prophylaxis may be justified in these patients," he told Reuters Health by email.
Continue reading article: http://www.chronicliverdisease.org/reuters/article.cfm?article=20180202Scie222294352
Thus Article Hep B reactivation common during direct-acting antiviral therapy for hep C
That's an article Hep B reactivation common during direct-acting antiviral therapy for hep C This time, hopefully can give benefits to all of you. well, see you in posting other articles.
You are now reading the article Hep B reactivation common during direct-acting antiviral therapy for hep C with the link address https://theleknews.blogspot.com/2018/02/hep-b-reactivation-common-during-direct.html
0 Response to "Hep B reactivation common during direct-acting antiviral therapy for hep C"
Post a Comment